A carregar...
Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells
BACKGROUND: The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse. Thus, new therapeutic strategies which could selectively target LSCs in...
Na minha lista:
| Publicado no: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034521/ https://ncbi.nlm.nih.gov/pubmed/27658462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0327-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|